A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers. Led by Co-director Ralph Weichselbaum, investigator Wenbin Lin and postdoctoral researcher Kaiting Yang at the Ludwig Center at Chicago, the study describes the synthesis, mechanism of action and preclinical assessment of the nanoparticle, which is loaded with a drug that activates a protein central to the efficient induction of anti-cancer immunity.
Lire la suiteEvery age in the history of human civilisation has a signature material, from the Stone Age, to the Bronze and Iron Ages. We might even call today’s information-driven society the Silicon Age.
Since the 1960s, silicon nanostructures, the building-blocks of microchips, have supercharged the development of electronics, communications, manufacturing, medicine, and more.
